James Nokes/Vaccine

Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach.Pan-Ngum W, Kinyanjui T, Kiti M, Taylor S, Toussaint JF, Saralamba S, Van Effelterre T, Nokes DJ, White LJ
Vaccine, (2017). 35:403-409

Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya.Nyiro JU, Sande C, Mutunga M, Kiyuka PK, Munywoki PK, Scott JA, Nokes DJ
Vaccine, (2015). 33:1797-801

The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants.Sande CJ, Cane PA, Nokes DJ
Vaccine, (2014). 32:4726-9

Strategic priorities for respiratory syncytial virus (RSV) vaccine development.Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS
Vaccine, (2013). 31 Suppl 2:B209-15

Evaluation of a measles vaccine campaign in Ethiopia using oral-fluid antibody surveys.Nigatu W, Samuel D, Cohen B, Cumberland P, Lemma E, Brown DW, Nokes J
Vaccine, (2008). 26:4769-74

Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules.Wilson JN, Nokes DJ, Medley GF, Shouval D
Vaccine, (2007). 25:3705-12